Association between pulse pressure and markers of cognitive function: a systematic review and meta-analysis.

J HypertensJul 24, 2026 (epub)
Clinical ResearchNeurologyGeriatrics

Olivia Gaunt, Kaavya Venkatesh, Ryan McNally et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between pulse pressure (PP) and cognitive function across 43 studies. The analysis revealed a positive association between PP and global cognition, while indicating a negative association with memory. The findings were derived from both cross-sectional and longitudinal studies, highlighting the complexity of these relationships.

Key findings

  • Meta-analysis indicates a positive association between pulse pressure and global cognition.
  • A negative association was found between pulse pressure and memory.
  • Processing speed, executive function, and language showed negative associations with pulse pressure in cross-sectional studies.
  • Limited evidence was found for associations with attention and visuospatial ability.

Why it matters

Understanding the relationship between pulse pressure and cognitive function is crucial for clinicians, as it may inform strategies for monitoring and managing cognitive health in aging populations.

Source

PubMed · PMID 42517337

Published in J Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.